Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaMultiple Myeloma Refractory; Multiple Myeloma in RelapseRecruitingPhase 22026-09-21NCT07096778

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
CellCentric Ltd.3

31 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
American Oncology Partners, PABethesdaUnited States5
Barts Health NHS TrustLondonUnited Kingdom13
Cleveland ClinicClevelandUnited States558
Dana-Farber Cancer InstituteBostonUnited States626
Fred Hutchinson Cancer CenterSeattleUnited States250
Froedtert Hospital & the Medical College of WisconsinMilwaukeeUnited States31
H Lee Moffitt Cancer Center & Research InstituteTampaUnited States2
Imperial College Healthcare NHS Trust, Hammersmith HospitalLondonUnited Kingdom3
John Theurer Cancer Center at Hackensack University Medical CenterHackensackUnited States37
King's College Hospital NHS Foundation TrustLondonUnited Kingdom31
Levine Cancer InstituteCharlotteUnited States110
Mayo ClinicRochesterUnited States664
Mayo Clinic ArizonaPhoenixUnited States55
Mayo Clinic FloridaJacksonvilleUnited States105
Oxford University Hospitals NHS Foundation TrustOxfordUnited Kingdom15
Royal Marsden NHS Foundation TrustSuttonUnited Kingdom1
Rutgers Cancer Institute of New JerseyNew BrunswickUnited States67
The Christie NHS Foundation TrustWithingtonUnited Kingdom1
The Clatterbridge Cancer Centre NHS Foundation TrustBebingtonUnited Kingdom4
University Hospital of WalesCardiffUnited Kingdom10
University Hospital Southampton NHS Trust, Southampton General HospitalSouthamptonUnited Kingdom1
University of California, San FranciscoSan FranciscoUnited States294
University of Chicago Medical CenterChicagoUnited States152
University of Iowa Health CareIowa CityUnited States47
University of MichiganAnn ArborUnited States538